Interest of β-blockers in patients with right ventricular systemic dysfunction

Cardiology in the Young

Volumn 20, Issue 6, 2010, Pages 615-619

  Bouallal, Rachid ^a   Godart, François ^a   Francart, Charles ^a   Richard, Adélaïde ^a   Foucher Hossein, Claude ^a   Lions, Christophe ^a  

^a UNIV LILLE   (France)

Author keywords

Cardiac failure; congenitally corrected transposition; transposition

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; PROPRANOLOL;

ADULT; AEROBIC CAPACITY; ARTICLE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GREAT VESSELS TRANSPOSITION; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART SURGERY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; RADIOISOTOPE VENTRICULOGRAPHY; TREATMENT FAILURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BISOPROLOL; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; STROKE VOLUME; TRANSPOSITION OF GREAT VESSELS; VENTRICULAR DYSFUNCTION, RIGHT; YOUNG ADULT;

EID: 78649976048     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951110000764     Document Type: Article

References (22)

1. Connelly MS, Liu PP, Williams WG, Webb GD, Robertson P, McLaughlin PR. Congenitally corrected transposition of the great arteries in the adult: functional status and complications. J Am Coll Cardiol 1996; 27: 1238-1243.
2. Graham TP, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: A multi-institutional study. J Am Coll Cardiol 2000; 36: 255-261.
3. Dos L, Teruel L, Ferreira IJ, et al. Late outcome of Senning and Mustard procedures for correction of transposition of the great arteries. Heart 2005; 91: 652-656.
4. Turina MI, Siebenmann R, Von Segesser L, Schönbeck M, Senning A. Late functional deterioration after atrial correction for transposition of the great arteries. Circulation 1989; 80: 162-167.
5. Rickli H, Steiner S, Müller K, Hess OM. Betablockers in heart failure: carvedilol safety assessment (CASA 2-trial). Eur J Heart Fail 2004; 6: 761-768.
6. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999; 33: 924-931.
7. Arnold RH, Kotlyar E, Hayward C, Keogh AM, Macdonald PS. Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: A single centre, observational study. Heart 2003; 89: 293-298.
8. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 102: 506-507.
9. Thackray SD, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006; 152: 713.e9-713.e13.
10. Ramahi TM, Longo MD, Cadariu AR, et al. Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in non ischemic cardiomyopathy. J Am Coll Cardiol 2001; 37: 818-824.
11. The Cardiac insufficiency bisoprolol study II (CIBIS-II Investigators and Committees): A randomised trial. Lancet 1999; 353: 9-13.
12. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis. Eur Heart J 2007; 28: 457-462.
13. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US carvedilol heart failure study group. N Engl J Med 1996; 334: 1349-1355.
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF Investigators and Committees). Lancet 1999; 353: 2001-2007.
15. Van der Zedde J, Oosterhof T, Tulevski II, Vliegen HW, Mulder BJ. Comparison of segmental and global systemic ventricular function at rest and during dobutamine stress between patients with transposition and congenitally corrected transposition. Cardiol Young 2005; 15: 148-153.
16. Espinola-Zavaleta N, Alexanderson E, Attié F, et al. Right ventricular function and ventricular perfusion defects in adults with congenitally corrected transposition: correlation of echocardiography and nuclear medicine. Cardiol Young 2004; 14: 174-181.
17. Tulevski II, Zijta FM, Smeijers AS, Dodge-Khatami A, van der Wall EE, Mulder BJ. Regional and global right ventricular dysfunction in asymptomatic or minimally symptomatic patients with congenitally corrected transposition. Cardiol Young 2004; 14: 168-173.
18. Lubiszewska B, Gosiewska E, Hoffman P, et al. Myocardial perfusion and function of the systemic right ventricle in patients after atrial switch procedure for complete transposition: long-term follow-up. J Am Coll Cardiol 2000; 36: 1365-1370.
19. Trojnarska O. Heart failure in the adult patient with congenital heart disease. Cardiol J 2007; 14: 127-136.
20. Doughan AR, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol 2007; 99: 704-706.
21. Giardini A, Lovato L, Donti A, et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol 2006; 114: 241-246.
22. Winter MM, Bouma BJ, van Dijk AP, et al. Relation of physical activity, cardiac function, exercise capacity and quality of life in patients with a systemic right ventricle. Am J Cardiol 2008; 102: 1258-1262.